Invivyd to announce Phase 3 COVID-19 trial results Monday
Invivyd, Inc. (NASDAQ:IVVD) is set to announce the results of its Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate designed to treat COVID-19, on Monday, November 23, 2026. The company will host an investor call at 8:30 a.m. ET following the announcement, which is expected to be made at 7:00 a.m. ET. VYD2311, developed using Invivyd’s technology platform, shares a similar antibody backbone with pemivibart and adintrevimab, both of which have received emergency use authorization for specific COVID-19 treatments.
The trial results will be made available on the company’s investor website via a webcast replay approximately two hours after the call concludes.
Brief written by urgent.news; may contain errors — check the original.
Source: investing.com